Nirav N. Shah, MD

Associate Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Gujarati

Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Nirav Shah, MD, MSHP, is Assistant Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in lymphoma, CAR-T cell therapy, and stem cell transplant at Froedtert Hospital. He graduated with honors and Alpha Omega Alpha Honor Society membership from the University of Illinois at Chicago College of Medicine in 2008. He then completed his Internal Medicine residency at Massachusetts General Hospital in Boston, Massachusetts in 2011. Post-residency, he took a position at Northwestern Memorial Hospital in Hospitalist medicine before proceeding to the University of Pennsylvania where he completed both hematology/oncology fellowship and a Master’s degree in Health Policy research in 2015.

Research Interests

Dr. Shah's current clinical and research interests include developing new cell based and immune therapies for patients with non-Hodgkin and Hodgkin lymphoma. He is specifically involved in the development of new CAR-T cell therapies for blood cancers. His professional memberships include the American Society of Hematology and the American Society of Clinical Oncology.

Dr. Shah is board certified by the American Board of Internal Medicine (ABIM) in Hematology, Medical Oncology, and Internal Medicine.

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.

(Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Brown JR.) Haematologica. 2024 Oct 03 PMID: 39363864 10/04/2024
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial.

(Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, Patel MR, Lamanna N, Tsai DE, Nair B, Wang C, Zhao X, Liu D, Radtke D, Chapman S, Marella N, McNeely SC, Brown JR.) Blood. 2024 Sep 26;144(13):1374-1386 PMID: 38861666 PMCID: PMC11451378 SCOPUS ID: 2-s2.0-85198077615 06/11/2024
Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation.

(Akhtar OS, Arshad S, Lian Q, Ahn KW, D'Souza A, Dhakal B, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, Hamadani M.) Transplant Cell Ther. 2024 Sep 18 PMID: 39303985 SCOPUS ID: 2-s2.0-85206435293 09/21/2024
Point-of-Care CAR-T Manufacturing Solutions: Can One Model Fit All?

(Urbano-Ispizua Á, Shah NN, Kekre N.) Blood Adv. 2024 Sep 12 PMID: 39265170 09/12/2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.

(Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P.) Lancet Haematol. 2024 Sep;11(9):e682-e692 PMID: 39033770 SCOPUS ID: 2-s2.0-85200244218 07/22/2024
Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention.

(Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M.) Blood Adv. 2024 Aug 27;8(16):4320-4329 PMID: 38889435 PMCID: PMC11372811 SCOPUS ID: 2-s2.0-85203009004 06/18/2024
Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States.

(Peloquin S, Cymbalista F, Dreyling M, Shah NN, Murray S, Del Fiacco R, Muehlenbein CE, Lazure P.) BMC Cancer. 2024 Aug 13;24(1):1003 PMID: 39138575 PMCID: PMC11321192 SCOPUS ID: 2-s2.0-85201250614 08/14/2024
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission.

(Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, Hamadani M.) Blood Cancer J. 2024 Jul 08;14(1):108 PMID: 38977682 PMCID: PMC11231252 SCOPUS ID: 2-s2.0-85197736867 07/09/2024
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies.

(Roeker LE, Coombs CC, Shah NN, Jurczak W, Woyach JA, Cheah CY, Patel K, Maddocks K, Wang Y, Zinzani PL, Munir T, Koh Y, Thompson MC, Muehlenbein CE, Wang C, Sizelove R, Abhyankar S, Hasanabba S, Tsai DE, Eyre TA, Wang M.) Acta Haematol. 2024 Jun 05:1-17 PMID: 38824917 06/03/2024
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.

(Karmali R, Machhi R, Epperla N, Shouse G, Romancik J, Moyo TK, Kenkre V, Ollila TA, Fitzgerald L, Hess B, David K, Roy I, Zurko J, Chowdhury SM, Annunzio K, Ferdman R, Bhansali RS, Harris EI, Liu J, Nizamuddin I, Ma S, Moreira J, Winter J, Pro B, Stephens DM, Danilov A, Shah NN, Cohen JB, Barta SK, Torka P, Gordon LI.) Blood Adv. 2024 May 28;8(10):2592-2599 PMID: 38531057 PMCID: PMC11145749 SCOPUS ID: 2-s2.0-85195045599 03/26/2024
Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion.

(Watt KD, Rolak S, Foley DP, Plichta JK, Pruthi S, Farr D, Zwald FO, Carvajal RD, Dudek AZ, Sanger CB, Rocco R, Chang GJ, Dizon DS, Langstraat CL, Teoh D, Agarwal PK, Al-Qaoud T, Eggener S, Kennedy CC, D'Cunha J, Mohindra NA, Stewart S, Habermann TH, Schuster S, Lunning M, Shah NN, Gertz MA, Mehta J, Suvannasankha A, Verna E, Farr M, Blosser CD, Hammel L, Al-Adra DP.) Transplantation. 2024 May 21 PMID: 38771067 05/21/2024
The role of noncovalent BTK inhibitors in the era of covalent BTK inhibitors.

(Furqan F, Shah NN.) Clin Adv Hematol Oncol. 2024 Apr;22(3):140-147 PMID: 38588273 SCOPUS ID: 2-s2.0-85190320304 04/08/2024